Answers are grounded in this paper and cite their sources.
Transplant patients are at particular risk for developing post-transplant lymphoproliferative disease (PTLD) following administration of immunosuppressive therapy. In many cases the PTLD lesions express Epstein-Barr virus (EBV) latent and lytic genes as well as elevated levels of host cytokines. An outline of the potential contributions of EBV, host cytokines and T cells, and the immunosuppressive cyclosporine A, tacrolimus, and anti-CD3 antibody in the mechanism and pathogenesis of this disease is presented and discussed.
No takes yet. Share an insight, caveat, or question.
Tanner et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: